For the quarter ended March 2025, Cencora (COR) reported revenue of $75.45 billion, up 10.3% over the same period last year. EPS came in at $4.42, compared to $3.80 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $74.82 billion, representing a surprise of +0.85%. The company delivered an EPS surprise of +8.33%, with the consensus EPS estimate being $4.08.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Cencora performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Total International Healthcare Solutions: $7.17 billion versus the four-analyst average estimate of $7.36 billion. The reported number represents a year-over-year change of +0.7%.
- Revenue- Total U.S. Healthcare Solutions: $68.28 billion versus the four-analyst average estimate of $67.56 billion. The reported number represents a year-over-year change of +11.4%.
- Revenue- Intersegment eliminations: -$3.71 million versus the three-analyst average estimate of -$2.49 million. The reported number represents a year-over-year change of +88.1%.
- Revenue- International Healthcare Solutions- Alliance Healthcare: $5.77 billion compared to the $5.98 billion average estimate based on two analysts. The reported number represents a change of +0.3% year over year.
- Revenue- U.S. Healthcare Solutions- Animal Health: $1.36 billion versus the two-analyst average estimate of $1.49 billion. The reported number represents a year-over-year change of +4.2%.
- Revenue- International Healthcare Solutions- Other Healthcare Solutions: $1.40 billion compared to the $1.42 billion average estimate based on two analysts. The reported number represents a change of +2.4% year over year.
- Revenue- U.S. Healthcare Solutions- Human Health: $66.92 billion versus the two-analyst average estimate of $65.56 billion. The reported number represents a year-over-year change of +11.6%.
View all Key Company Metrics for Cencora here>>>
Shares of Cencora have returned +5.9% over the past month versus the Zacks S&P 500 composite's +10.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cencora, Inc. (COR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
